Keith E Volmar, Michael O Idowu, Rhona J Souers, Raouf E Nakhleh1. 1. From the Department of Pathology, Rex Pathology Associates, Raleigh, North Carolina (Dr Volmar); the Department of Pathology, Virginia Commonwealth University, Richmond (Dr Idowu); the Department of Biostatistics, College of American Pathologists, Northfield, Illinois (Ms Souers); and the Department of Pathology, Mayo Clinic Jacksonville, Jacksonville, Florida (Dr Nakhleh).
Abstract
CONTEXT: The appropriate and timely performance of molecular testing in anatomic pathology is an indicator of quality. The National Comprehensive Cancer Network (NCCN) publishes a comprehensive treatment guideline that includes recommendations for ancillary testing. OBJECTIVE: To establish benchmarks for rates of adherence to NCCN testing recommendations through a multi-institutional study. DESIGN: Participants in a 2013 Q-Probes study of the College of American Pathologists reported data from molecular testing on anatomic pathology cases, excluding hematolymphoid neoplasms, breast primary carcinomas, and gynecologic cytology. RESULTS: Twenty-six institutions reported data from 2230 molecular testing events. In a retrospective study limited to colon, lung, and melanoma, there was strict adherence to guidelines in a median 71% (10th to 90th percentile range, 33%-90%) and there was at least loose adherence in a median 95% (10th to 90th percentile range, 57%-100%). There was adequate tissue to complete testing in a median 98% (10th to 90th percentile range, 86%-100%); in aggregate the adequacy rate for cell blocks was lower (84%, P < .001). Median test turnaround time was 8 days (10th to 90th percentile range, 4-13 days). In a prospective collection of all organ sites, there was strict adherence to guidelines in a median 53% (10th to 90th percentile range, 20%-71%), and there was at least loose adherence in a median 94% (10th to 90th percentile range, 75%-100%). Adherence to guidelines was higher for lung specimens and in institutions with more multidisciplinary conferences. CONCLUSIONS: This multi-institutional study provides benchmarking data on appropriateness and timeliness of molecular testing in anatomic pathology.
CONTEXT: The appropriate and timely performance of molecular testing in anatomic pathology is an indicator of quality. The National Comprehensive Cancer Network (NCCN) publishes a comprehensive treatment guideline that includes recommendations for ancillary testing. OBJECTIVE: To establish benchmarks for rates of adherence to NCCN testing recommendations through a multi-institutional study. DESIGN:Participants in a 2013 Q-Probes study of the College of American Pathologists reported data from molecular testing on anatomic pathology cases, excluding hematolymphoid neoplasms, breast primary carcinomas, and gynecologic cytology. RESULTS: Twenty-six institutions reported data from 2230 molecular testing events. In a retrospective study limited to colon, lung, and melanoma, there was strict adherence to guidelines in a median 71% (10th to 90th percentile range, 33%-90%) and there was at least loose adherence in a median 95% (10th to 90th percentile range, 57%-100%). There was adequate tissue to complete testing in a median 98% (10th to 90th percentile range, 86%-100%); in aggregate the adequacy rate for cell blocks was lower (84%, P < .001). Median test turnaround time was 8 days (10th to 90th percentile range, 4-13 days). In a prospective collection of all organ sites, there was strict adherence to guidelines in a median 53% (10th to 90th percentile range, 20%-71%), and there was at least loose adherence in a median 94% (10th to 90th percentile range, 75%-100%). Adherence to guidelines was higher for lung specimens and in institutions with more multidisciplinary conferences. CONCLUSIONS: This multi-institutional study provides benchmarking data on appropriateness and timeliness of molecular testing in anatomic pathology.
Authors: Dara L Aisner; Mathew D Rumery; Daniel T Merrick; Kimi L Kondo; Hala Nijmeh; Derek J Linderman; Robert C Doebele; Natalie Thomas; Patrick C Chesnut; Marileila Varella-Garcia; Wilbur A Franklin; D Ross Camidge Journal: Arch Pathol Lab Med Date: 2016-09-09 Impact factor: 5.534
Authors: Ridgely Fisk Green; Mary Ari; Katherine Kolor; W David Dotson; Scott Bowen; Nancy Habarta; Juan L Rodriguez; Lisa C Richardson; Muin J Khoury Journal: Genet Med Date: 2018-06-15 Impact factor: 8.822